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Abstract 
Purpose: To determine whether a combination L-carnitine and α-lipoic acid (ALA) can alleviate the toxic 
effects of thioacetamide (TAA) via their potent antioxidant and free radical-scavenging activities.  
Methods: Rats were injected with TAA for 3 days to induce acute hepatic failure. TAA induced rats 
were treated with each of lactulose, L-carnitine and ALA alone and a combination of L-carnitine and 
ALA for 3 months. Thereafter, biochemical indices, ammonia levels, oxidative stress markers, and the 
levels of inflammatory markers were assessed in serum, liver and brain. 
Results: A significant improvement was observed after 3 months of antioxidants treatment.  Lactulose, 
L-carnitine and ALA significantly decreased serum concentrations of alanine transaminase (ALT), 
aspartate aminotransaminase (AST) and  level of total bilirubin while both levels of total protein (TP) and 
albumin (ALB) were significantly increased (p < 0.05 ) compared to TAA group. In addition, each of 
antioxidants alone significantly decreased ammonia (NH3) concentrations of serum, liver and brain in 
TAA-induced rats. Treatment with antioxidants for 3 months  significantly (p < 0.05) decreased 
Malondialdehyde (MDA) and nitric oxide (NO) while antioxidant enzyme activities of glutathione 
peroxidase (GPX) and superoxide dismutase (SOD) were significantly increased (p < 0.05) in liver and 
brain tissues. The expressions of serum tumor necrosis factor-α (TNF-α) and soluble protein (S100-β) 
were significantly (p < 0.05) down-regulated in TAA-induced rats. 
Conclusion: L-carnitine in combination with ALA can mitigate HE induced experimentally in rats. The 
protective efficacy of L-carnitine in combination with ALA in HE can be attributed to suppression of 
oxidative stress, ammonia concentration and the levels of inflammatory markers.  Thus, it may have the 
potential to be used to treat liver cirrhosis in clinical settings. 
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HE is a neuropsychiatric syndrome that occurs in 
both cirrhosis and acute liver failure (ALF). HE is 
a significant cause of morbidity and mortality in 
advanced cirrhotic patients. Affected patients 
exhibit alterations in psychomotor, intellectual, 
cognitive, emotional and behavioral. In addition 
to, hyperammonemia is responsible for both 
direct and indirect alterations in cerebral 
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metabolism in HE [1]. TAA is a thiocarbonyl 
compound which has been used as a fungicide, 
organic solvent, and stabilizer of motor oil. TAA-
induced acute liver failure is used as acute liver 
injury model and it has  been  widely  studied  in  
rats  and  in  other  animal species  using  
different  doses,  times  and routes  of  
administration. Moreover, biochemical and 
histological changes observed in human cirrhosis 
are similar to those observed in experimental 
TAA-induced liver cirrhosis [2]. 
 
There are a few therapeutic strategies, and 
outcome expectations for patients with HE.  
Lactulose is a synthetic, non-digestible sugar 
used in the treatment of chronic constipation and 
HE. It is a disaccharide formed from 
monosaccharide (fructose and galactose) and it 
is produced commercially by isomerization of 
lactose. Lactulose has been shown to improve 
quality of life and cognitive function in patients 
with cirrhosis and minimal hepatic 
encephalopathy.  Moreover, lactulose therapy 
can improve blood ammonia and reduce the risk 
of developing overt encephalopathy. Recently, it 
remains the mainstay therapy for HE [3]. 
 
L-carnitine and its acyl- derivatives are as 
potential antioxidants and low-cost therapeutic 
agents [4]. In animal models, L-carnitine has 
been shown to counteract neurotoxic effects of 
ammonia, improve energy metabolism and 
greater improvements in neuropsychological 
functioning [5]. Furthermore, L-carnitine 
supplementation has hepatoprotective effect, 
maintained and improved liver function as well as 
patients with liver cirrhosis (LC) [6].    
 
ALA and  its  reduced  form  dihydrolipoic acid 
(DHLA), are  natural  compounds  widely  
distributed  in plants  and  animals. They are  
synthesized  through  a reaction  catalyzed  by  
lipoic  acid  sysnthase  within  the mitochondria 
of the liver, heart and kidney. ALA Possesses a 
unique antioxidant ALA/DHLA system. Thus, 
DHLA is able to reduce not only reactive oxygen 
species (ROS) but also oxidize forms of other 
antioxidants [7]. Due to thiol groups and free 
thiols, ALA is essential in GSH synthesis, thereby 
maintaining maximum levels of other antioxidants 
such as vitamins C and E, SOD and catalase 
(CAT) [8].  ALA also easily penetrates all cells 
and tissues of the body, including the blood brain 
barrier (BBB) and increases the synthesis of 
acetylcholine and thereby maintains the integrity 
of the brain [9]. 
 
Accordingly, this study aims to explore the 
protective efficacy of  Lactulose, L-carnitine and 
ALA treatment and the combination L-carnitine 






The protocol for the present study was approved 
by the Research Ethics Committee at the Faculty 
of Science – Ain Shams University, Egypt (REC 
– FS ref. no. 00032). 
 
Eighty adult male albino rats weighing 120 - 150 
g were obtained from the Animal House Colony 
of the National Research Centre, Cairo, Egypt 
and allowed to acclimate to the animal facility for 
one week prior to the experiment. The rats were 
housed at 25 ± 2 °C with a 12-h light-dark cycle.   
 
The animals received a standard pellet diet and 
tap water ad libitum compliance with the 
guidelines of the National Research Council 
(NRC) [10]. 
 
Induction of acute liver injury to rats  
 
TAA is extensively used as a model of acute 
hepatic failure. TAA dissolved in physiological 
saline and induced fulminant hepatic failure 
through three consecutive i.p injections of TAA 
(100 mg/kg i.p) to rats daily for 3 consecutive 
days. 
 
Drugs and doses 
 
In the current study, the pharmacological doses 
of lactulose, L- carnitine and ALA were applied 
(8 mg/kg/day, 100 mg/kg/day and 
100 mg/kg/day, respectively). Lactulose, L- 
carnitine and ALA were prepared in sterile 
distilled water and administered orally. 
 
TAA was purchased from Sigma Chem. Co. (St. 
Louis, Mo, USA). Lactulose, L-carnitine and ALA 
were purchased from EVA PHARMA Egypt. 
Each 100 ml of Lactulose contain 65 mg of 
Lactulose. Each capsules of L-carnitine contains 
350 mg of L-carnitine while each capsules of 
ALA contains 600 mg of ALA. 
 
Experimental design and protocol 
 
After one week acclimatization, eight groups 
were formed (n = 10) and treated as follows:  
 
Group (1): rats injected daily 1 mL physiological 
saline i.p for 3 days (control group 3 days). 
Group (2): rats received TAA (100 mg/kg i.p) for 
3 consecutive days (TAA 3 days). Group (3): rats 
injected daily 1 ml physiological saline i.p for 3 
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days and left untreated for 3 months (control 
group 3 months). Group (4): rats administered 
TAA (100 mg/ kg i.p) daily for 3 consecutive days 
and left untreated for 3 months (TAA 3 months). 
Group (5): rats received TAA (100 mg/kg i.p) 
daily for 3 consecutive days and then treated 
with lactulose (8 ml/kg. orally) daily for 3 months 
(TAA+ lactulose). Group (6): rats received TAA 
(100 mg/kg. i.p) daily for 3 consecutive days and 
then treated with L-carnitine (100 mg/kg orally) 
daily for 3 months (TAA+ L-carnitine). Group (7): 
rats injected TAA (100 mg/kg i.p) daily for 3 
consecutive days and then treated with ALA (100 
mg/kg orally) daily for 3 months (TAA+ α-lipoic 
acid). Group (8): rats received TAA (100 mg/kg 
i.p) daily for 3 consecutive days and then treated 
with a combined dose of both L-carnitine and 
ALA daily for 3 months (TAA+ L-carnitine+ α-
lipoic acid).  
 
At the end of the experimental period, the 
animals were fasted for 12 h, and blood samples 
were collected from the retro–orbital venous 
plexus in clean dry test tubes under diethyl ether 
anesthesia. The blood samples were centrifuged 
at 1800 xg for 15 min at 4 ˚C. Sera were 
separated and stored at 20 ˚C for biochemical 
analyses. 
 
Preparation of liver and brain homogenates 
 
After blood collection, all animals were sacrificed 
by decapitation and the whole liver and brain of 
each animal were rapidly excised, thoroughly 
washed with isotonic saline and blotted dry. 
Subsequently, the liver and brain were weighed 
and a portion of each tissue was homogenized. 
Liver was immediately homogenized in 50 mM 
ice-cold phosphate buffer (pH 7.4) to give 20 
%w/v homogenate according to Lin et al [11]. 
The brain was immediately homogenized to give 
10 %w/v homogenate in an ice-cold medium 
containing 50 mM Tris-Hcl and 300 mM sucrose, 
pH 7.4 as described by Tsakiris [12]. The 
homogenates were centrifuged at 1800xg for 10 
min in refrigerated centrifuge at 4 °C. The 
supernatants of the liver and brain tissue 
homogenate were separated for biochemical 
analyses. 
 
Determination of serum ALT, AST, TP, ALB 
and bilirubin 
 
The activities of serum ALT and AST were 
determined spectrophotometrically using an 
automated analyzer method (Opera Technician 
Bayer Auto analyzer). Serum total protein (TP) 
level was determined by colorimetric point 
method.  Serum albumin (ALB) level was 
determined by quantitative colorimetric method.  
Serum total bilirubin level was determined by 
colorimetric method. 
 
Assessment of serum, liver and brain 
ammonia level 
 
Ammonia (NH3) level was measured using 
standard kits, based on the absorbance 
photometry method of phenate-hypochlorate 
reaction. 
 
Evaluation of MDA and NO levels 
 
Malondialdehyde (MDA) levels were assayed by 
monitoring thiobarbituric acid reactive substance 
formation. The principle of the method is the 
spectrophotometric measurement of the color 
generated by the reaction of thiobarbituric acid 
substance (TBA) with MDA. Lipid peroxidation 
was expressed in terms of MDA equivalents 
using an extinction coefficient of 1.56 × 105 M-1 
cm-1 and the levels of MDA were expressed as 
nmol MDA/g tissue. The commercial ELISA kit of 
MDA and nitric oxide (NO) were purchased from 
Oxford Biomedical Research Inc., USA. 
 
Determination of GPX and SOD activities 
 
The activities of Glutathione peroxidase (GPX) 
and superoxide dismutase (SOD) were 
measured by ELISA technique using commercial 
kits (Gesellschaft, Hamburg Germany). 
 
Analysis of serum α -TNF-α and S100-β level 
 
Serum tumor necrosis factor-α (TNF-α) level was 
assayed by ELIZA technique using TNF-α assay 
kit purchased from Glory Science Co., Ltd, TX, 
USA and quantitative determination of serum 
soluble protein S100-β) was carried out using 





Data are expressed as mean ± SE and were 
evaluated by one-way analysis of variance 
(ANOVA) followed by least significant difference 
(LSD) test using SPSS, version 10 software. P < 





Administration of TAA (100 mg/kg, i.p) showed 
significant elevation in serum marker enzyme 
activities (ALT and AST) and serum bilirubin level 
with significant decline in serum TP and ALB 
levels (Table 1). 
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Table 1: Effect of lactulose, L-carnitine, ALA and the combined dose of L-carnitine and ALA on serum liver 
function tests in TAA-induced HE in rats 
 
Group ALT AST TP ALB Bilirubin 
(U/L) (U/L) (g/dL) (g/dL) (mg/dL) 
Normal control (3 days) 30.07 ±0.50 55.0 ±0.63 7.77 ±0.02 4.11 ±0.03 0.923 ±0.04 
TAA (3 days) 177.97 ±2.63a 186.14 ±2.03a 4.80 ±0.03a 2.17 ±0.01a 2.28 ±0.06 a 
Normal control (3 months) 29.71  ± 0.42 54.50 ±0.57 7.80 ±0.02 4.11 ±0.02 1.00 ±0.05 
TAA (3 months) 321.0  ± 5.18b 342.45 ±3.83b 4.21 ±0.03b 1.89 ±0.03 b 3.54 ±0.06 b 
TAA + Lactulose 139.75  ± 1.38c 125.57 ±2.13c 6.03 ±0.05c 3.50 ±0.0 2 c 1.70 ±0.01 c 
TAA + L-carnitine 170.0  ±2.20cd 166.42 ±2.90cd 5.67 ±0.05cd 2.89 ±0.21 cd 2.20 ±0.01 cd 
TAA +  ALA 187.86  ± 2.58cde 196.58 ±2.91cde 5.54 ±0.04 cde 2.50 ±0.02cde 2.40 ±0.02 cde 
TAA + L-carnitine + ALA 156.43  ± 1.86cdef 153.85 ±2.87cdef 5.81 ±0.04cdef 3.00 ±0.03cdef 1.90±0.01cdef 
Values represent mean ± SE, number of samples is 10 rats per group; a; b; c; d; e; f Significant at p < 0.05 
between the groups in the same rows 
 
Lactulose, L-carnitine and ALA (8 mg/kg /day, 
100 mg/kg /day and 100 mg/kg /day, 
respectively) treatment of HE – induced rats 
resulted in a significant improvement in the levels 
of these parameters compared to the HE group. 
The ammonia concentrations was significantly 
higher (p < 0.05) in the serum, liver and brain of 
HE group compared to control rats whereas it 
was significantly lower in Lactulose, L-carnitine 
and ALA groups (Table 2). 
 
The liver and brain MDA and NO levels were 
significantly increased (p < 0.05) in the HE group 
than in the control whereas GPX and SOD 
activities were significantly lower (p < 0.05). 
Lactulose, L-carnitine and ALA treatment rats 
showed that MDA and NO levels significantly 
declined (p < 0.05) whereas GPX and SOD 
activities were significantly increased (Table 3, 
Table 4). 
 
Table 2: Effect of lactulose, L-carnitine, ALA and the combined dose of L-carnitine and ALA on 
serum, liver and brain ammonia levels in TAA-induced HE in rats 
 
Group Serum ammonia 
(μmol/mL) 
Liver ammonia 
(μmol/g wet tissue) 
Brain ammonia 
(μmol/g wet tissue) 
Normal control (3 days) 0.21±0.002 0.60±0.01 0.33±0.01 
TAA (3 days) 1.02±0.014 a 2.44±0.040a 0.62±0.01 a 
Normal control (3 months) 0.21±0.003 0.60±0.01 0.33±0.01 
TAA (3 months) 1.48±0.003b 3.88±0.10 b 1.12±0.02 b 
TAA + Lactulose 0.63±0.008 c 1.65±0.03 c 0.64±0.02 c 
 TAA + L-carnitine 0.93±0.012cd 1.95±0.02 cd 0.97±0.003cd 
TAA + ALA 1.07±0.04 cde 2.10±0.03 cde 0.99 ±0.01cd 
TAA + L-carnitine + ALA 0.75±0.007 cdef 1.85 ±0.03 cdf 0.82 ±0.02cdef 
Values represent mean ± SE, number of samples is 10 rats per group; a; b; c; d; e; f Significant at p < 
0.05 between the groups in the same rows 
 
Table 3: Effect of lactulose, L-carnitine, ALA and the combined dose of L-carnitine and ALA on liver 












Normal control (3 days) 17.79 ±0.15 5.58 ±0.11 1.15 ±0.01 99.70 ±0.96 
TAA (3 days) 34.82 ±0.39a 13.47 ±0.05a 0.81 ±0.01a 81.70 ±0.73a 
Normal control (3 months) 17.96 ±0.09 5.46 ±0.08 1.15 ±0.01 98.82 ±1.00 
TAA (3 months) 52.22 ±0.64b 21.08 ±0.19b 0.65 ±0.01b 69.26 ±0.50b 
TAA + Lactulose 25.00 ±0.34c 13.64 ±0.21c 0.98 ±0.07c 88.00 ±0.07 c 
TAA + L-carnitine 29.99 ±0.34cd 15.18 ±0.21cd 0.78 ±0.04cd 78.00 ±0.05cd 
TAA + ALA 32.00 ±0.33  cde 15.72 ±0.25cde 0.70 ±0.07d 74.00 ±0.03  cde 
TAA + L-carnitine + ALA 28.02 ±0.28 cdef 14.5 ±0.21 cdef 0.85 ±0.05cdf 82.00 ±0.04 cdef 
Values represent mean ± SE, number of samples is 10 rats per group; a; b; c; d; e; f Significant at p < 
0.05 between the groups in the same rows. 
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Table 4: Effect of lactulose, L-carnitine, ALA and the combined dose of L-carnitine and ALA on brain 












Normal control  (3 days) 5.82 ±0.08 29.93±0.36 1.27 ±0.02 3.06 ±0.02 
TAA (3 days) 8.47 ±0.04a 37.01 ±0.42a 0.87 ±0.01a 2.20 ±0.02a 
Normal control (3 months) 5.86 ±0.07 29.64  ±0.29 1.26 ±0.02 3.05 ±0.03 
TAA (3 months) 12.90 ±0.11b 55.53 ±0.63b 0.56 ±0.02b 1.39 ±0.02b 
TAA + Lactulose 8.00 ±0.26c 38.00 ±0.12c 1.09 ±0.0c 2.79 ±0.04c 
TAA + L-carnitine 8.99 ±0.14cd 42.48 ±0.18cd 0.83 ±0.03cd 2.00 ±0.02cd 
TAA +  ALA 9.99 ±0.15 cde 43.86 ±0.14cde 0.75 ±0.03cde 1.80 ±0.03 cde 
TAA + L-carnitine +  ALA 8.50 ±0.19cde 41.00 ±0.14cdef 0.90 ±0.03cd 2.30 ±0.04 cdef 
Values represent mean ± SE, number of samples is 10 rats per group; a; b; c; d; e; f Significant at p < 
0.05 between the groups in the same rows. 
 
Table 5: Effect of lactulose, L-carnitine, ALA and the combined dose of L-carnitine and ALA on serum 








Normal control (3 days) 7.79 ±0.03 26.74 ±0.16 
TAA (3 days) 16.37 ±0.19a 46.06 ±0.53a 
Normal control (3 months) 7.83 ±0.03 26.90 ±0.06 
TAA (3 months) 45.24 ±0.84b 137.94 ±3.91b 
TAA + Lactulose 20.00 ±0.11c 54.96 ±0.95c 
TAA + L-carnitine 24.99 ±0.11cd 62.98 ±1.74cd 
TAA + ALA 26.99 ±0.39cde 65.00 ±0.72cd 
TAA + L-carnitine + ALA 23.00 ±0.08cdef 59.00 ±1.39cf 
Values represent mean ± SE, number of samples is 10 rats per group; a; b; c; d; e; f Significant at p < 
0.05 between the groups in the same rows 
 
Serum inflammatory marker levels were 
significantly higher of HE rats (p < 0.05) than in 
those of control rats. The oral administration of 
Lactulose, L-carnitine and ALA (8 mg/kg /day, 
100 mg/kg /day and 100 mg/kg /day, 
respectively) resulted in a substantial (p < 0.05) 
reduction in TNF-α and S100-β levels compared 
to the HE group (Table 5). 
 
In the current investigation, Lactulose, L-carnitine 
and ALA treatment (8 mg/kg /day, 
100 mg/kg /day and 100 mg/kg /day, 
respectively) demonstrated significant protective 
effect in all studied parameters whereas the 
antioxidant activity of the L-carnitine in 




HE occurs in both acute and chronic liver 
disease and there is a good correlation between 
blood ammonia and severity of HE. 
Hyperammonemia plays a major role in the 
development of brain edema and in evoking 
changes in cerebral blood flow (CBF) [13]. There 
are several drugs and clinical trials that could 
benefit patients with HE and most of them tend to 
reduce the production and absorption of 
ammonia from the colon, with the hypothesis that 
the colon is the primary organ that generates 
ammonia [14]. Recently, it was recorded that 
lactulose is the most commonly utilized non-
absorbable disaccharide for prophylaxis of HE 
[15]. 
 
In the current work, marked amelioration has 
been detected in the all studied parameters after 
treatment of TAA-intoxicated group with lactulose 
for 3 months. Marked improvement in liver 
functions as indicated through detectable 
decrease in serum ALT, AST and bilirubin levels 
with significant elevation in TP and ALB levels. 
This effect may be attributable to conversion of 
ammonia to poorly absorbable ammonium ion 
and decrease in ammonia production by 
bacteria. Lactulose showed significant reduction 
in serum, liver and brain ammonia levels. The 
present results are consistent with the previous 
study reporting that lactulose could significantly 
lower the level of hyperammonemia [16]. 
 
In the present investigation, lactulose can 
significantly restore the balance between 
oxidants and antioxidant of liver and brain in 
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TAA-intoxicated group compared with the 
untreated ones. This finding is represented by 
the reduction of pro-oxidants (MDA and NO) with 
activation of the antioxidant enzymes (GPX and 
SOD). These results are due to reduction of 
oxidative stress in hepatocytes leading to 
increased hepatic clearance of ammonia in HE 
rat model. Lactulose and molecular hydrogen 
has been found to activate the expression of Nrf2 
and they could indirectly activate the 
endogenous antioxidant system [17].  
 
The anti-inflammatory effect of lactulose has 
been demonstrated in the current study through 
down-regulation of serum TNF-α and S100β 
levels. The current data is consistent with Zhai et 
al [18] who showed the ability of Lactulose to 
perform hepatoprotective and neuroprotective 
effects due to its free radical- scavenging.  
 
The present data revealed that oral 
administration of L-carnitine to TAA-intoxicated 
rats significantly reduced serum levels of ALT, 
AST and bilirubin level while significantly 
increased serum TP and ALP levels. These 
results could be attributed to the direct 
antioxidant action of L-carnitine with 
hepatoprotective effect that enable it to protect 
plasma membranes from the attacking of free 
radicals and prevent their damage. Furthermore, 
L-carnitine exerts protective effects against 
cerebral energy distortions and neuronal 
dysfunction in HE suggesting that L-carnitine 
acts as a potential therapeutic agent in metabolic 
encephalopathy such as ammonia-precipitated 
HE [19].  
 
The concomitant reduction in serum, liver and 
brain ammonia concentrations as a consequence 
of L-carnitine supplementation as shown in the 
present study confirm the effect of L-carnitine on 
ammonia clearance that prevent acute ammonia 
toxicity and reduce its effects on the brain with 
significant improvement in the cellular redox 
state as well as mitochondrial energy 
metabolism.  
 
In the present investigation, L-carnitine could 
significantly maintain balance between pro-
oxidants and antioxidants in the liver and brain of 
TAA- intoxicated rats. Also, L-carnitine exhibits 
antioxidant effect by reducing metabolic stress 
and showed significant suppression in MDA and 
NO production associated with a significant 
elevation in GPX and SOD activities in liver and 
brain tissues [20]. The anti-inflammatory activity 
of L-carnitine has been demonstrated in the 
current study through decreasing serum TNF-α 
and S100- β levels in TAA+ L-carnitine group 
suggesting that carnitine played a major role in 
controlling the level of circulating cytokines and 
to the suppression of neutrophil infiltration [21].   
 
Several studies have focused on the antioxidant 
properties of ALA. ALA is effective in both 
prevention and treatment of oxidative stress in a 
number of models and clinical conditions 
including ischemia-reperfusion injury, diabetes, 
HIV infection and neurodegenerative diseases 
[22]. In light of the obtained data, oral 
administration of ALA in HE rats inhibited the 
development of liver cirrhosis through significant 
attenuation of serum ALT, AST activities and 
bilirubin level with significant modulation of TP 
and ALP levels. Moreover, the beneficial effects 
of ALA treatment on HE rats have been indicated 
through marked correction of serum, liver and 
brain ammonia levels. These results suggest that 
ALA restored the deficiency of glutamine 
synthesize flow into the cells with consequent 
increment in glutamine production and correction 
of ammonia utilization [23]. In addition AA 
administration significantly reduced MDA and 
SOD levels and significantly improved the 
activities of GPX and SOD in liver and brain 
tissues. The protective effect of ALA is derived 
from its ability to counteract ROS generation and 
exhibited beneficial role in the treatment of 
chronic liver diseases [24]. ALA treatment of HE 
– induced rats significantly decremented serum 
TNF-α and S100- β levels.  Concentrations, 
consistent with its anti- inflammatory potential. 
 
In the present study, L-carnitine in combination 
with ALA was effective in the treatment of 
chemically induced liver fibrosis in rats. All 
parameters were significantly (p < 0.05) 
ameliorated. Their antioxidant mechanisms 
involve the inhibition of oxidative stress, 
inflammation, level of hyperammonemia as well 
as metabolic disturbances in TAA - induced liver 
and brain Tissues. Therefore, their combination 
may be used as a potential hepatoprotective, 




The findings of this study indicate that the 
combination of L-carnitine and ALA exerts 
significant antioxidant, anti-inflammatory and 
anti-fibrotic activities, and thus possesses 
hepatoprotective and neuroprotective effect. 
Therefore, the combination product has the 
potentials to be developed for the management 
of liver cirrhosis. 
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